These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29903674)

  • 21. Immunogenicity and safety of the non-typable
    Galgani I; Põder A; Jõgi R; Anttila VJ; Milleri S; Borobia AM; Launay O; Testa M; Casula D; Grassano L; Tasciotti A; Dozot M; Arora AK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2187194. PubMed ID: 36974988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
    Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
    Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
    MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
    Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
    Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
    Naficy A; Kuxhausen A; Pirrotta P; Leav B; Miller J; Anteyi K; Danier J; Breuer T; Mwakingwe-Omari A
    Clin Infect Dis; 2023 Nov; 77(9):1238-1246. PubMed ID: 37335963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
    Schmader KE; Levin MJ; Chen M; Matthews S; Riley ME; Woo W; Hervé C; Grupping K; Schuind AE; Oostvogels L; Curran D
    J Gerontol A Biol Sci Med Sci; 2021 Feb; 76(3):485-490. PubMed ID: 32530462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
    Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
    J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
    Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
    Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.